EuropaBio welcomes the European Commission commitment to initiate the Industrial Decarbonisation Accelerator (IDA) Act as part of the Clean Industrial Deal. Biotechnology and biomanufacturing are of high strategic importance to achieve the EU’s net-zero ambitions and should be included in the IDA Act as essential for EU competitiveness. This would also boost industrial confidence.

Biotechnologies play an essential role for the delivery of EU goals for competitive, healthy, resilient and sustainable economies and societies. Biotech is a driver of high value and disruptive innovation. It is also unique as it enables the production of biologically active and structurally complex molecules that conventional chemistry cannot generally manufacture or produce efficiently. This makes biotechnology applications indispensable in health, agri-food,
chemicals, the manufacturing of consumer goods and more throughout our industrial and social ecosystems. They are a hallmark of success, demonstrating EU growth and benefit through innovation. The EU must therefore urgently prioritise their scale-up and access to EU and global markets, as this will be vital for the EU to stay in the global race of clean and disruptive technologies. The IDA Act can also support the objectives of the Critical Medicines Act of increasing manufacturing capacity in the EU and promote more sustainable production of medicines.

Read and download the full position below